Logo image of NRXS

NEURAXIS INC (NRXS) Stock Fundamental Analysis

NYSEARCA:NRXS - NYSE Arca - US64134X2018 - Common Stock - Currency: USD

2.5  -0.12 (-4.58%)

After market: 2.5 0 (0%)

Fundamental Rating

3

Taking everything into account, NRXS scores 3 out of 10 in our fundamental rating. NRXS was compared to 187 industry peers in the Health Care Equipment & Supplies industry. NRXS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, NRXS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NRXS had negative earnings in the past year.
In the past year NRXS has reported a negative cash flow from operations.
NRXS had negative earnings in each of the past 5 years.
In the past 5 years NRXS always reported negative operating cash flow.
NRXS Yearly Net Income VS EBIT VS OCF VS FCFNRXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

NRXS's Return On Assets of -291.25% is on the low side compared to the rest of the industry. NRXS is outperformed by 96.79% of its industry peers.
With a Return On Equity value of -3413.66%, NRXS is not doing good in the industry: 92.51% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -291.25%
ROE -3413.66%
ROIC N/A
ROA(3y)-1140.93%
ROA(5y)-815%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NRXS Yearly ROA, ROE, ROICNRXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

With an excellent Gross Margin value of 85.86%, NRXS belongs to the best of the industry, outperforming 97.33% of the companies in the same industry.
NRXS's Gross Margin has improved in the last couple of years.
NRXS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.51%
GM growth 5YN/A
NRXS Yearly Profit, Operating, Gross MarginsNRXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

5

2. Health

2.1 Basic Checks

NRXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
NRXS has more shares outstanding than it did 1 year ago.
NRXS has a better debt/assets ratio than last year.
NRXS Yearly Shares OutstandingNRXS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M
NRXS Yearly Total Debt VS Total AssetsNRXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1M 2M 3M 4M

2.2 Solvency

Based on the Altman-Z score of -29.14, we must say that NRXS is in the distress zone and has some risk of bankruptcy.
NRXS has a Altman-Z score of -29.14. This is amonst the worse of the industry: NRXS underperforms 91.44% of its industry peers.
There is no outstanding debt for NRXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -29.14
ROIC/WACCN/A
WACC9.08%
NRXS Yearly LT Debt VS Equity VS FCFNRXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M -2M -4M -6M

2.3 Liquidity

NRXS has a Current Ratio of 1.21. This is a normal value and indicates that NRXS is financially healthy and should not expect problems in meeting its short term obligations.
NRXS has a worse Current ratio (1.21) than 81.82% of its industry peers.
A Quick Ratio of 1.19 indicates that NRXS should not have too much problems paying its short term obligations.
NRXS has a Quick ratio of 1.19. This is in the lower half of the industry: NRXS underperforms 72.19% of its industry peers.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 1.19
NRXS Yearly Current Assets VS Current LiabilitesNRXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

4

3. Growth

3.1 Past

NRXS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 94.70%, which is quite impressive.
NRXS shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.16%.
NRXS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.42% yearly.
EPS 1Y (TTM)94.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.15%
Revenue 1Y (TTM)27.16%
Revenue growth 3Y-0.42%
Revenue growth 5YN/A
Sales Q2Q%38.57%

3.2 Future

Based on estimates for the next years, NRXS will show a very negative growth in Earnings Per Share. The EPS will decrease by -23.86% on average per year.
The Revenue is expected to grow by 20.13% on average over the next years. This is a very strong growth
EPS Next Y-880%
EPS Next 2Y-125.83%
EPS Next 3Y-23.86%
EPS Next 5YN/A
Revenue Next Year31306.7%
Revenue Next 2Y2520.16%
Revenue Next 3Y20.13%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NRXS Yearly Revenue VS EstimatesNRXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2B 4B 6B 8B
NRXS Yearly EPS VS EstimatesNRXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NRXS. In the last year negative earnings were reported.
Also next year NRXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRXS Price Earnings VS Forward Price EarningsNRXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRXS Per share dataNRXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A cheap valuation may be justified as NRXS's earnings are expected to decrease with -23.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-125.83%
EPS Next 3Y-23.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NRXS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEURAXIS INC

NYSEARCA:NRXS (8/1/2025, 8:04:02 PM)

After market: 2.5 0 (0%)

2.5

-0.12 (-4.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)N/A N/A
Inst Owners11.49%
Inst Owner Change1.76%
Ins Owners21.17%
Ins Owner Change-38.73%
Market Cap23.43M
Analysts82.5
Price Target6.38 (155.2%)
Short Float %0.26%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-324.75%
Min EPS beat(2)-614.71%
Max EPS beat(2)-34.8%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-89.64%
Min Revenue beat(2)-99.88%
Max Revenue beat(2)-79.41%
Revenue beat(4)0
Avg Revenue beat(4)-83.98%
Min Revenue beat(4)-99.88%
Max Revenue beat(4)-77.59%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)31.58%
EPS NQ rev (1m)10.87%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-99.9%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.98
P/FCF N/A
P/OCF N/A
P/B 90.62
P/tB 142.4
EV/EBITDA N/A
EPS(TTM)-1.21
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0.31
BVpS0.03
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -291.25%
ROE -3413.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.86%
FCFM N/A
ROA(3y)-1140.93%
ROA(5y)-815%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.51%
GM growth 5YN/A
F-Score4
Asset Turnover0.97
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 92.84%
Cap/Sales 1.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.21
Quick Ratio 1.19
Altman-Z -29.14
F-Score4
WACC9.08%
ROIC/WACCN/A
Cap/Depr(3y)133.32%
Cap/Depr(5y)94.99%
Cap/Sales(3y)2.06%
Cap/Sales(5y)1.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.15%
EPS Next Y-880%
EPS Next 2Y-125.83%
EPS Next 3Y-23.86%
EPS Next 5YN/A
Revenue 1Y (TTM)27.16%
Revenue growth 3Y-0.42%
Revenue growth 5YN/A
Sales Q2Q%38.57%
Revenue Next Year31306.7%
Revenue Next 2Y2520.16%
Revenue Next 3Y20.13%
Revenue Next 5YN/A
EBIT growth 1Y-0.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3Y-12.8%
EBIT Next 5YN/A
FCF growth 1Y-128.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-133.33%
OCF growth 3YN/A
OCF growth 5YN/A